Diabetes (Type 2)

  • Published: 7 October 2021
  • 1 min read

PERsonalised Medicine for Intensification of Treatment (PERMIT): the case of type 2 Diabetes Mellitus

Addressing priority 6: NIHR research in progress

Most people with Type 2 diabetes start treatment with a drug called metformin, but some are later obliged to take additional drugs when the metformin is not effective enough. It is unclear which of the additional drugs is best for which patient, and there is variation across the UK in the choice of drug. Ideally, the choice of the additional drug should be 'personalised' according to patient differences such as age or weight. This study will investigate how metformin and the additional drugs have been used and how different patients have responded in respect of improvements in their health.

Dietary Approaches to the Management Of type 2 Diabetes (DIAMOND) cluster randomised trial

Addressing priorities 5, 7 and 10: NIHR research in progress

This research aims to show whether a low energy low carbohydrate food-based diet and support from practice nurses can help people with recently diagnosed type 2 diabetes achieve remission, meaning no need for diabetes medicines.

The Utility Of Frequency-Modulated Electromagnetic Neural Stimulation (FREMS) As A Third Line Treatment In Patients With Painful Diabetes-Related Peripheral Neuropathy: A Randomised Controlled Trial (FREMS-PDPN)

Addressing priority 8: NIHR research in progress

This study aims to evaluate the efficacy of FREMS (Frequency Rhythmic Electrical Modulated System) in patients with painful diabetic peripheral neuropathy (PDPN, painful feet from nerve damages caused by diabetes) who have not responded to the NICE (National Institute for Health and Care Excellence) recommended treatments. FREMS delivers electrical pulses via stickers that are placed on the feet and legs; these pulses can reduce the pain in patients with PDPN.

Further information about research that has been funded in this area is included here.